|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | National Heart, Lung, and Blood Institute (NHLBI) |
|---|---|
| Information provided by: | National Heart, Lung, and Blood Institute (NHLBI) |
| ClinicalTrials.gov Identifier: | NCT00000484 |
Purpose
To determine whether the long-term treatment of essential hypertension without significant target organ disease materially influenced mortality and/or cardiovascular renal morbidity.
| Condition | Intervention | Phase |
|---|---|---|
|
Cardiovascular Diseases Heart Diseases Hypertension Vascular Diseases |
Drug: chlorothiazide Drug: Rauwolfia alkaloids |
Phase III |
| Study Type: | Interventional |
| Study Design: | Prevention, Randomized, Double-Blind, Placebo Control |
| Study Start Date: | April 1966 |
BACKGROUND:
This grant-supported, cooperative, fixed-protocol clinical study was initiated in 1966 and followed a cooperative study of the treatment of renal hypertension initiated in 1960 to evaluate the relative efficacy of several recognized drug regimens for reduction of blood pressure. Six centers (USPHS hospitals) and a coordinating center were involved in the trial.
DESIGN NARRATIVE:
Randomized, double-blind, fixed sample. Three hundred and eighty nine eligible patients were assigned to drug therapy consisting of chlorothiazide plus Rauwolfia serpentina or to placebo.
Eligibility| Ages Eligible for Study: | 21 Years to 55 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Men and women, ages 21-55. Mild essential hypertension (diastolic blood pressure over 90 mm Hg.
Contacts and Locations| Investigator: | Anthony Damato | USPHS Hospital |
| Investigator: | Richard Thurm | USPHS Hospital |
| Investigator: | Christfried Urner | USPHS Hospital |
| Investigator: | John Vaillancourt | USPHS Hospital |
| Investigator: | J. Warbasse | USPHS Hospital |
| Investigator: | Robert Wells | USPHS Hospital |
More Information
| Study ID Numbers: | 3 |
| Study First Received: | October 27, 1999 |
| Last Updated: | June 23, 2005 |
| ClinicalTrials.gov Identifier: | NCT00000484 History of Changes |
| Health Authority: | United States: Federal Government |
|
Heart Diseases Molecular Mechanisms of Pharmacological Action Chlorothiazide Diuretics Physiological Effects of Drugs Sodium Chloride Symporter Inhibitors Vascular Diseases Cardiovascular Agents |
Antihypertensive Agents Pharmacologic Actions Membrane Transport Modulators Natriuretic Agents Therapeutic Uses Cardiovascular Diseases Hypertension |